Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Pharmaco Distribution (Pty) Ltd, 3 Sandown Valley Crescent, South Tower, First Floor, Sandton 2196, Gauteng, South Africa Ethical assistance Line: +27 (0) 784 00 77
Etilefrine hydrochloride belongs to the medicine class A 5.1 Adrenomimetics (sympathomimetics).
EFFORTIL in pharmacological terms is regarded as a sympathomimetic. Recent investigations allow for a more precise description as a cardio-selective drug. This term deserves some explanation: EFFORTIL has a mild stimulating effect on peripheral α-adrenoceptors (approximately 1/10 of that of noradrenaline), a mild stimulating effect of β2-adrenoceptors, and a prominent effect on β1-adrenoceptors.
The pharmacologically assessed action on adrenoceptors results in a number of typical cardiovascular changes. They are: increase in venous return, increase in stroke volume and cardiac output, unchanged heart rate, slight drop in peripheral arterial resistance, relaxation in precapillary sphincters and increase in transcapillary flow. By the same token, the circulation time is shortened. The combination of the above cardiovascular actions causes improved tissue perfusion. Based on the above considerations, EFFORTIL can be used in all conditions where a decreased tissue perfusion is assumed. One of the leading symptoms of reduced tissue perfusion is a drop in blood pressure.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
